Although FGFR1 and FGFR2 fusions were less frequent overall, FGFR1 was relatively common in breast cancer (0.4%) and FGFR2 in hepatobiliary/hepatocellular cancer (4.3%) (Figure S2A,S2B). Here, FGFR1 is linked to breast carcinoma.